ParoStop

Controlled release drug delivery systems of innovative and selective drug molecules for the treatment of bacterial infectious diseases of the periodontum ParoStop

The goal of the project is the development of locally applied controlled release drug delivery systems – CRDDS for innovative and selective drug candidates for the treatment of periodontitis. Deliverables will be prototypes of such pharmaceutical formulations containing several compound classes that are developed by PerioTrap Pharmaceuticals GmbH. Those formulations are subject to further testing in non-clinical and clinical studies within the ongoing drug development process of the company. Thereby, the project bridges the new pharmacological approach of targeting only the key-stone pathogens of periodontitis and simultaneously acting only locally. This combination causes only a very small systemic burden of the patient’s body and will minimize potential side effects including the generation of resistances against the new compound. The project is a joint project with two Fraunhofer institutions (Fraunhofer IZI-MWT and Fraunhofer IMWS) 

It started on February 8th, 2021 and will run until April 30th, 2022, and is funded by the German Federal State of Saxony-Anhalt with funds from the European Regional Development Fund (ERDF).